Loading patent…
AssigneeAkzo Nobel N.V.
InventorsRonald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessy, Karen K. Brown
Estimating the term…
The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.
A vaccine for effectively and safely immunizing mammals from disease caused by EIAV, said vaccine comprising a gene-mutated EIAV wherein said virus lacks the ability to express the mutated gene protein in vivo and wherein said lack of expression can be used to differentiate vaccinated from non-vaccinated or infected mammals.
A vaccine for protecting horses from disease caused by EIAV comprising a gene-mutated EIAV construct, said construct allowing a vaccinated horse to be differentiated from an EIAV infected horse.
A method of differentiating a vaccinated mammal from a non-vaccinated mammal, said method comprising;
A method of differentiating a vaccinated mammal from a non-vaccinated mammal, said method comprising;
A method of immunizing a horse against EIAV comprising vaccinating said horse with an EIAV vaccine comprising a gene-mutated EIAV and an adjuvant.
A method of immunizing a horse against EIAV comprising vaccinating said horse with an EIAV vaccine comprising a gene-mutated EIAV, an inactivating agent and an adjuvant
Dependencies are inferred from the claim text.